Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Atrophy, Geographic
Interventions: GSK933776, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 55 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more

Conditions: RSV Immunisation
Interventions: RSVt Vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 21 Months
Enrollment: 6,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more

Conditions: Awake Fiberoptic Intubation
Interventions: Dexmedetomidine HCL Injection, Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 17
States / cities: Birmingham, Alabama • Loma Linda, California • Miami, Florida + 12 more

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: CELIVARONE (SSR149744C); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: BIIB091, DRF, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 23
States / cities: Scottsdale, Arizona • Berkeley, California • Orange, California + 20 more

Conditions: Muscle Atrophy, Hypodynamia
Interventions: HPP593, Placebo; Drug
Lead sponsor: High Point Pharmaceuticals, LLC.; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: Ulcerative Colitis, Colitis, Ulcerative
Interventions: VE202, Vancomycin Oral Capsule, VE202 Placebo, Vancomycin Placebo; Biological · Drug · Other
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Naples, Florida • Orlando, Florida • Decatur, Georgia + 6 more

Conditions: Brain Death, Respiration, Artificial
Interventions: Hope inVent; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 1 Year to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dyslipidemia
Interventions: PRC-4016, Placebo; Drug
Lead sponsor: Pronova BioPharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 33 more

Conditions: Postbariatric Hypoglycemia
Interventions: exendin 9-39, Placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions: Airiver ESSpand DCB, ESS; Combination Product · Procedure
Lead sponsor: Airiver Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • San Diego, California + 11 more

Conditions: Ocular Hypertension, Open-angle Glaucoma
Interventions: Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Migraine
Interventions: Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 41
States / cities: Phoenix, Arizona • Long Beach, California • National City, California + 36 more

Conditions: HIV Associated Diarrhea
Interventions: Crofelemer 125 mg, Crofelemer 250 mg, Crofelemer 500 mg, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 79
States / cities: Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more

Conditions: Healthy
Interventions: JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Postoperative Pain
Interventions: Bupivacaine HCl, SKY0402; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Birmingham, Alabama • Davis, California • Laguna Hills, California + 3 more

Conditions: Osteoarthritis
Interventions: RN624 (PF-04383119), placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Lateral Canthal Lines
Interventions: RT001, Placebo; Drug · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more

Conditions: Social Anxiety Disorder (SAD)
Interventions: ENX-102, Placebo; Drug · Other
Lead sponsor: Engrail Therapeutics INC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 16 more

Conditions: End Stage Renal Disease, Vascular Access Patency
Interventions: ticagrelor, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 17, ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1
Interventions: CAD-1883, Placebos; Drug
Lead sponsor: Cadent Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Diabetic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 7,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 173
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more

Conditions: Type II Diabetes
Interventions: AZD1656, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Search by objective public record fields.

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Safety Study of HPP593 in Subjects During and After Limb Immobilization

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Miniature In-line Respirator

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

Study of CAD-1883 for Spinocerebellar Ataxia

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes